{"entity":{"id":"izabright-breast01","kind":"trial","name":"IZABRIGHT-Breast01","aka":[],"tldr":"IZABRIGHT-Breast01 is the global first-line trial of the EGFR×HER3 bispecific ADC in triple-negative breast cancer.","summary":"IZABRIGHT-Breast01, trial NCT06926868 sponsored by Bristol Myers Squibb, is the global first-line trial of the EGFR by HER3 bispecific antibody-drug conjugate izalontamab brengitecan in metastatic triple-negative breast cancer patients ineligible for PD-1 or PD-L1 inhibitors, comparing it with chemotherapy. It plans to enrol 570 patients, directly competes for the populations studied in ASCENT-03 and TROPION-Breast02, and is ongoing with no results. OnCo links it to triple-negative breast cancer, izalontamab brengitecan and the TNBC roadmap. Whether a bispecific ADC that succeeded in a Chinese phase 3 can match or beat the approved TROP2 ADCs in a global first-line population is the question it exists to answer.","status":"recruiting","asOf":"2026-09-04","links":[{"label":"ClinicalTrials.gov NCT06926868","url":"https://clinicaltrials.gov/study/NCT06926868"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["adc","bispecific-adc"],"targets":[],"drugs":["izalontamab-brengitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06926868","phase":"2/3","setting":"First-line metastatic TNBC ineligible for PD-(L)1 inhibitors: iza-bren vs chemotherapy","sponsor":"BMS","started":"2025-09-11","startedType":"actual","enrolled":570,"enrolledBasis":"registry","outcomes":[],"replication":"Ongoing; no results."},"route":"/trials/izabright-breast01/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"}],"drug":[{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/"}],"roadmap":[{"id":"tnbc-history","kind":"roadmap","name":"TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line","route":"/roadmaps/tnbc-history/"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"idea":[{"id":"idea-tnbc-brain-metastasis-trials","kind":"idea","name":"Trials that include, and report, brain metastases in triple-negative breast cancer","route":"/ideas/idea-tnbc-brain-metastasis-trials/"}]}}